Market Cap
US$7.5b
Last Updated
2021/04/12 22:03 UTC
Data Sources
Company Financials +
Executive Summary
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 5.7% per year for the next 3 years
Snowflake Analysis
Flawless balance sheet with solid track record.
Similar Companies
Share Price & News
How has Chemed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CHE is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: CHE's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
0.09%
CHE
0.6%
US Healthcare
0.9%
US Market
1 Year Return
3.2%
CHE
42.4%
US Healthcare
57.9%
US Market
Return vs Industry: CHE underperformed the US Healthcare industry which returned 40.8% over the past year.
Return vs Market: CHE underperformed the US Market which returned 56.3% over the past year.
Shareholder returns
| CHE | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.09% | 0.6% | 0.9% |
| 30 Day | 4.6% | 2.8% | 2.3% |
| 90 Day | -13.1% | 3.3% | 6.3% |
| 1 Year | 3.5%3.2% | 44.2%42.4% | 60.8%57.9% |
| 3 Year | 65.0%63.4% | 52.5%46.1% | 64.5%53.9% |
| 5 Year | 241.4%234.1% | 90.7%76.4% | 120.9%96.4% |
Long-Term Price Volatility Vs. Market
How volatile is Chemed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Here's Why We Think Chemed (NYSE:CHE) Is Well Worth Watching2 weeks ago | Simply Wall St
Need To Know: Chemed Corporation (NYSE:CHE) Insiders Have Been Selling Shares1 month ago | Simply Wall St
Shareholders Are Thrilled That The Chemed (NYSE:CHE) Share Price Increased 241%Valuation
Is Chemed undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CHE ($465.37) is trading below our estimate of fair value ($1149.62)
Significantly Below Fair Value: CHE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CHE is good value based on its PE Ratio (23.2x) compared to the US Healthcare industry average (24.5x).
PE vs Market: CHE is poor value based on its PE Ratio (23.2x) compared to the US market (22.3x).
Price to Earnings Growth Ratio
PEG Ratio: CHE's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: CHE is overvalued based on its PB Ratio (8.2x) compared to the US Healthcare industry average (3.6x).
Future Growth
How is Chemed forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
-5.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CHE's earnings are forecast to decline over the next 3 years (-5.7% per year).
Earnings vs Market: CHE's earnings are forecast to decline over the next 3 years (-5.7% per year).
High Growth Earnings: CHE's earnings are forecast to decline over the next 3 years.
Revenue vs Market: CHE's revenue (2.6% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: CHE's revenue (2.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CHE's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Chemed performed over the past 5 years?
24.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CHE has a large one-off gain of $75.1M impacting its December 31 2020 financial results.
Growing Profit Margin: CHE's current net profit margins (15.4%) are higher than last year (11.3%).
Past Earnings Growth Analysis
Earnings Trend: CHE's earnings have grown significantly by 24.7% per year over the past 5 years.
Accelerating Growth: CHE's earnings growth over the past year (45.2%) exceeds its 5-year average (24.7% per year).
Earnings vs Industry: CHE earnings growth over the past year (45.2%) exceeded the Healthcare industry 20.5%.
Return on Equity
High ROE: CHE's Return on Equity (35.4%) is considered high.
Financial Health
How is Chemed's financial position?
Financial Position Analysis
Short Term Liabilities: CHE's short term assets ($329.4M) exceed its short term liabilities ($299.1M).
Long Term Liabilities: CHE's short term assets ($329.4M) exceed its long term liabilities ($234.6M).
Debt to Equity History and Analysis
Debt Level: CHE is debt free.
Reducing Debt: CHE has no debt compared to 5 years ago when its debt to equity ratio was 18%.
Debt Coverage: CHE has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CHE has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Chemed current dividend yield, its reliability and sustainability?
0.29%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CHE's dividend (0.29%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.26%).
High Dividend: CHE's dividend (0.29%) is low compared to the top 25% of dividend payers in the US market (3.5%).
Stability and Growth of Payments
Stable Dividend: CHE is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: CHE is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: CHE is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CHE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
17.1yrs
Average management tenure
CEO
Kevin McNamara (66 yo)
19.92yrs
Tenure
US$10,019,850
Compensation
Mr. Kevin J. McNamara has been the Chief Executive Officer of Chemed Corp. since May 2001 and has been its President since August 2, 1994. Previously, Mr. McNamara served as an Executive Vice President and...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD10.02M) is above average for companies of similar size in the US market ($USD6.40M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: CHE's management team is seasoned and experienced (17.1 years average tenure).
Board Members
Experienced Board: CHE's board of directors are seasoned and experienced ( 12.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Chemed Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Chemed Corporation
- Ticker: CHE
- Exchange: NYSE
- Founded: 1970
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$7.461b
- Shares outstanding: 16.03m
- Website: https://www.chemed.com
Number of Employees
Location
- Chemed Corporation
- 255 East Fifth Street
- Suite 2600
- Cincinnati
- Ohio
- 45202-4726
- United States
Listings
Biography
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United Stat...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/12 22:03 |
| End of Day Share Price | 2021/04/12 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.